

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2003/0162738	08/28/03	Egyed <i>et al.</i>	514	44	12/06/02
	A2	5,663,153	09/02/97	Hutcherson <i>et al.</i>	514	44	06/06/95
	A3	5,683,864	11/04/97	Houghton <i>et al.</i>	435	5	07/07/92
	A4	5,723,335	03/03/98	Hutcherson <i>et al.</i>	435	375	09/11/96
	A5	6,037,135	03/14/00	Kubo <i>et al.</i>	435	7.24	11/29/93
	A6	6,150,087	11/21/00	Chien	435	5	05/18/95
	A7	6,413,517	07/02/02	Sette <i>et al.</i>	424	185.1	01/21/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	A 1973/2000	11/23/00	Austria	English
	B2	A 805/2001	05/21/00	Austria	English
	B3	EP 0 468 520	01/29/92	Europe	English
	B4	WO 00/11186	03/02/00	WIPO	English
	B5	WO 00/23105	04/27/00	WIPO	English
	B6	WO 00/31542	06/02/00	WIPO	English
	B7	WO 00/44775	08/03/00	WIPO	English
	B8	WO 01/17551	03/15/01	WIPO	English
	B9	WO 01/21189	03/29/01	WIPO	English
	B10	WO 01/24822	04/12/01	WIPO	English
	B11	WO 01/54719	08/02/01	WIPO	English
	B12	WO 01/72782	10/04/01	WIPO	English
	B13	WO 01/78767	10/25/01	WIPO	English

25766598.1

EXAMINER: /E.L./	DATE CONSIDERED: 08/07/2008
------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Buschle <i>et al.</i>	
		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B14	WO 01/93903	12/13/01	WIPO	English
	B15	WO 01/93905	12/13/01	WIPO	English
	B16	WO 02/053185	07/11/02	WIPO	English
	B17	WO 02/095027	11/28/02	WIPO	English
	B18	WO 02/13857	02/21/02	WIPO	English
	B19	WO 02/32451	04/25/02	WIPO	English
	B20	WO 02/33127	04/25/02	WIPO	English
	B21	WO 03/047602	06/12/03	WIPO	English
	B22	WO 03/073097	09/04/03	WIPO	English
	B23	WO 2004/014936	02/19/04	WIPO	French (English Abstract)
	B24	WO 2004/024182	03/25/04	WIPO	English
	B25	WO 92/03458	03/05/92	WIPO	English
	B26	WO 93/00365	01/07/93	WIPO	English
	B27	WO 94/20127	09/15/94	WIPO	English
	B28	WO 94/25601	11/10/94	WIPO	English
	B29	WO 95/12766	05/11/95	WIPO	English
	B30	WO 95/22317	08/24/95	WIPO	English
	B31	WO 95/25122	09/21/95	WIPO	English
	B32	WO 95/27733	10/19/95	WIPO	English
	B33	WO 95/27901	10/19/95	WIPO	English
	B34	WO 96/02555	02/01/96	WIPO	English
	B35	WO 97/30721	08/28/97	WIPO	German (English Abstract)
	B36	WO 98/15287	04/16/98	WIPO	English

25766598.1

EXAMINER: /E.L./	DATE CONSIDERED: 08/07/2008
------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B37	WO 98/16247	04/23/98	WIPO	English
	B38	WO 98/18810	05/07/98	WIPO	English
	B39	WO 98/37919	09/03/98	WIPO	English
	B40	WO 98/40100	09/17/98	WIPO	English
	B41	WO 98/52581	11/26/98	WIPO	English
	B42	WO 98/52962	11/26/98	WIPO	English
	B43	WO 99/15259	04/01/99	WIPO	English
	B44	WO 99/33488	06/08/99	WIPO	English
	B45	WO 99/38528	08/05/99	WIPO	German (English Abstract)
	B46	WO 99/51259	10/14/99	WIPO	English
	B47	WO 99/56755	11/11/99	WIPO	English
	B48	WO 99/63941	12/16/99	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	"Aluminumhydroxide," Röempf, 10 th Ed., pp. 139-140, 2006 (in German).
	C2	Anthony <i>et al.</i> , "Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy," <i>Clinical Immunology</i> , 103(3):264-276, 2002.
	C3	Battegay <i>et al.</i> , "Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules," <i>J. Virol.</i> , 69(4):2462-2470, 1995.
	C4	Bellentani <i>et al.</i> , "Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery," <i>Microbes Infect.</i> , 2(14):1757-63, 2000.
	C5	Bitmansour <i>et al.</i> , "Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus," <i>J Immunol</i> , 167:1151-1163, 2001.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Blake <i>et al.</i> , "Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes," <i>J. Exp. Med.</i> , 184:121-130, 1996.
	C7	Britt and Alford, "Cytomegalovirus," In: <i>Fields Virology</i> by Fields <i>et al.</i> eds., Livincott-Raven, 2493-2523 1999.
	C8	Bullock <i>et al.</i> "Initiation codon scanthrough verses termination codon readthrough demonstrates strong potential for MHC class I restricted cryptic epitope expression," <i>Journal of Experimental Medicine</i> , 186:1051-1058, 1997.
	C9	Chang <i>et al.</i> , "Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C," <i>J. Immunol.</i> , 162:1156-1164, 1999.
	C10	Chen <i>et al.</i> , "A novel influenza A virus mitochondrial protein that induces cell death; <i>Nature Medicine</i> , 7:1306-1312, 2001.
	C11	Chen <i>et al.</i> , "Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Bar virus-transformed B-lymphoblastoid cell lines to CD4+ T cells," <i>Journal of Virology</i> , 72(10):8301-8308, 1998.
	C12	Cho <i>et al.</i> , "Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLL-K-NH ₂ , via cell surface calreticulin," <i>Eur. J. Biochem.</i> , 266:878-885, 1999.
	C13	Cox <i>et al.</i> , "Identification of a peptide recognized by five melanoma-specific human cytotoxic t cell lines," <i>Science</i> , 264:716-719, 1994.
	C14	Di Bisceglie <i>et al.</i> , "New therapeutic strategies for hepatitis C," <i>Hepatology</i> , 35:224-231, 2002.
	C15	Diepolder <i>et al.</i> , "Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection," <i>J. Virol.</i> , 71(8):6011-6019, 1997.
	C16	Drew and Lalezari, "Cytomegalovirus: disease syndromes and treatment," <i>Curr Clin Top Infect Dis</i> , 19:16-29, 1999.
	C17	Duenas-Carrera <i>et al.</i> , "Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids," <i>Biotechnol. Appl. Biochem.</i> , 35:205-212, 2002.
	C18	Elliot <i>et al.</i> "Recognition of out-of-frame major histocompatibility complex class I-restricted epitopes <i>in vivo</i> ," <i>European Journal of Immunology</i> , 26:1175-1179, 1996.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C19	Farci and Purcell, "Clinical significance of hepatitis C virus genotypes and quasispecies," <i>Semin Liver Dis.</i> , 20(1):103-26, 2000.
	C20	Fleckenstein <i>et al.</i> , "New ligands binding to the human leukocyte antigen class II molecule DRB+0101 based on the activity pattern of an undecapeptide library," <i>European Journal of Biochemistry</i> , 240:71-77, 1996.
	C21	Greten and Schneck, "Development and use of multimeric major histocompatibility complex molecules," <i>Clinical and Diagnostic Laboratory Immunology</i> , 9(2):216-220, 2002.
	C22	Gruener <i>et al.</i> , "Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus," <i>J. Virol.</i> , 75:5550-5558, 2001.
	C23	Hammer <i>et al.</i> , "Promiscuous and allel-specific anchors in HLA-DR-binding peptides," <i>Cell</i> , 74:197-203, 1993.
	C24	Heemels and Ploegh, "Generation, translocation and presentation of mhc class I-restricted peptides," <i>Annu Rev Biochem</i> , 64:463-491, 1995.
	C25	Heile <i>et al.</i> , "Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates," <i>J. Virol.</i> , 74(15):6885-6892, 2000.
	C26	Hemmer <i>et al.</i> , "Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology," <i>J. Immunol.</i> , 160:3631-3636, 1998.
	C27	Hemmer <i>et al.</i> , "The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells," <i>J. Peptide Res.</i> , 52:338-345, 1998.
	C28	HLA-prevalence studies, In: HLA 1998, (Gjertson and Terasaki, eds.) American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas, pp. 103-263, 1998.
	C29	Hoffmann <i>et al.</i> , "Mapping of Immunodominant CD4+ T Lymphocyte Epitopes of Hepatitis C Virus Antigens and Their Relevance During the Course of Chronic Infection," <i>Hepatology</i> , 21(3):632-638, 1995.
	C30	Hunziker <i>et al.</i> , "In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus," <i>International Immunology</i> , 14(6):615-626, 2002.

25766598.1

EXAMINER: /E.L./	DATE CONSIDERED: 08/07/2008
------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents See Page 1		Foreign Patent Documents See Page 1-3	Other Art See Page 3-10

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation	
	C31	Ibe <i>et al.</i> , "Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B*3501 in acute hepatitis," <i>J. Gen. Virol.</i> , 79:1735-1744, 1998.	
	C32	Inchauspe and Feinstone, "Development of a hepatitis C virus vaccine," <i>Clinics in Liver Disease</i> , 7:243-259, 2003.	
	C33	Keilholz <i>et al.</i> , "Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy," <i>J Immunother.</i> , 25(2):97-138, 2002.	
	C34	Kern <i>et al.</i> , "Analysis of cd8 t cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides," <i>Eur J Immun.</i> , 30:1676-1682, 2000.	
	C35	Kern <i>et al.</i> , "Target structures of the cd8+-t-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited," <i>J Virol.</i> , 73:8179-8184, 1999.	
	C36	Klein, <i>Natural History of the MHC</i> , John Wiley and Sons, 1986.	
	C37	Komanduri <i>et al.</i> , "Restoration of cytomegalovirus-specific cd4+ t-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1," <i>Nat Med.</i> , 4:953-956, 1998.	
	C38	Koziel <i>et al.</i> , "Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV," <i>J. Virol.</i> , 67:7522-7532, 1993.	
	C39	Koziel <i>et al.</i> , "HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release," <i>J. Clin. Invest.</i> , 96:2311-2321, 1995.	
	C40	Kurokohchi <i>et al.</i> , "A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection," <i>J. Hepatology</i> , 34:930-935, 2001.	
	C41	Kwok <i>et al.</i> , "Rapid epitope identification from complex class-II-restricted T-cell antigens," <i>Trends in Immunology</i> , 22(11):583-588, 2001.	
	C42	Lamona <i>et al.</i> , "Conserved Hepatitis C Virus Sequences Are Highly Immunogenic for CD4+ T Cells: Implications for Vaccine Development," <i>Hepatology</i> , 30(4):1088-1098, 1999.	
	C43	Lauer <i>et al.</i> , "Comprehensive analysis of CD8+-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities," <i>Journal of Virology</i> , 76(12):6104-6113, 2002.	
	C44	Lechmann and Liang, "Vaccine development for hepatitis C," <i>Seminars in Liver Disease</i> , 20:211-226, 2000.	

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C45	Leroux-Roels <i>et al.</i> , "Lymphoproliferative Responses to Hepatitis C Virus Coes, E1, E2, and NS3 in Patients With Chronic Hepatitis C Infection Treated With Interferon Alfa," <i>Hepatology</i> , 23(1):8-16, 1996.
	C46	Liang <i>et al.</i> , "Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C," <i>Ann Intern Med.</i> , 132(4):296-305, 2000.
	C47	Maecker <i>et al.</i> , "Use of overlapping peptide mixtures as antigens for cytokine flow cytometry," <i>J Immunol Methods</i> , 255:27-40, 2001.
	C48	Malarkannan <i>et al.</i> , "Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism," <i>Immunity</i> , 10:681-690, 1999.
	C49	Maynard <i>et al.</i> "An alternative translation reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus," <i>J. of Immunology</i> , 160:39-50, 1998.
	C50	Maynard <i>et al.</i> "Non-traditionally derived CTL epitopes: exceptions that prove the rules?" <i>Immunology Today</i> , 19:551-556, 1998.
	C51	McCluskie <i>et al.</i> , "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA," <i>Fems Immunol and Medical Microbiol</i> , 32:179-185, 2002.
	C52	Morgan <i>et al.</i> , "The influence of exogenous peptide on beta2-microglobulin exchange in the HLA complex: analysis in real time," <i>Immunogenetics</i> , 48:98-107, 1998.
	C53	Nakajima <i>et al.</i> , "Chemotherapeutic activity of synthetic antimicrobial peptides: correlation between chemotherapeutic activity and neutrophil-activating activity," <i>FEBS Lett.</i> , 415:64-66, 1997.
	C54	Novak <i>et al.</i> , "Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4 ⁺ T cell epitopes from complex antigens," <i>The Journal of Immunology</i> , 166:6665-6670, 2001.
	C55	Parker <i>et al.</i> , "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>J. Immunol.</i> , 152:163, 1994.
	C56	Plotkin, "Vaccination against cytomegalovirus, the changeling demon," <i>Pediatr Infect Dis J</i> , 18:313-325, 1999.

25766598.1

EXAMINER: /E.L./	DATE CONSIDERED: 08/07/2008
------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's		Applicant Michael Buschle et al.	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: September 23, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C57	Rammensee <i>et al.</i> , "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50:213-219, 1999.
	C58	Reddehase, "The immunogenicity of human and murine cytomegaloviruses," <i>Curr Opin Immunol</i> , 12:390-396, 2000.
	C59	Rehermann <i>et al.</i> , "Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients," <i>J. Virol.</i> , 70(10):7092-7102, 1996.
	C60	Rollier <i>et al.</i> , "Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response," <i>J. Virol.</i> , 78(1):187-196, 2004.
	C61	Sarobe <i>et al.</i> , "Enhanced <i>in vitro</i> potency and <i>in vivo</i> immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions," <i>J. Clin. Invest.</i> , 102(6):1239-1248, 1998.
	C62	Shastri <i>et al.</i> , "Major histocompatibility class I molecules can present cryptic translation products to T-cells," <i>J. Biol. Chem.</i> 270:1088-1091, 1995.
	C63	Shirai <i>et al.</i> , "An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans," <i>J. Virol.</i> , 68(5):3334-3342, 1994.
	C64	Smith <i>et al.</i> , "Peptide sequences binding to MHC class II proteins," <i>Molecular Immunology</i> , 31:1431-1437, 1994.
	C65	Stern and Wiley, "Antigenic peptide binding by class I and class II histocompatibility proteins," <i>Structure</i> , 2:245-251, 1994
	C66	Stevens <i>et al.</i> , "Efficient generation of major histocompatibility complex class I-peptide complexes using synthetic peptide libraries," <i>Journal of Biological Chemistry</i> , 273:2874-2884, 1998.
	C67	Sturniolo <i>et al.</i> , "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17:555-562, 1999.
	C68	Tana <i>et al.</i> , "An HLA-binding-motif-aided peptide epitope library: a novel library design for the screening of HLA-DR4-restricted antigenic peptides recognized by CD4+ T cells," <i>J Hum Genet</i> , 43:14-21, 1998.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Group: 1645
		Other Art <i>See Page 3-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C69	Thursz <i>et al.</i> , "Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research," <i>Lancet</i> , 354(9196):2119-24, 1999.
	C70	Tobery <i>et al.</i> , "A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified elispot assay," <i>J Immunol Methods</i> , 254:59-66, 2001.
	C71	Tourdot <i>et al.</i> , "A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes," <i>Eur. J. Immunol.</i> 30:3411-3421, 2000.
	C72	Van den Eynde and van der Bruggen, "T cell defined tumor antigens," <i>Curr Opin Immunol</i> , 5:684-693, 1997.
	C73	Varaklioti <i>et al.</i> , "Alternative translation occurs within the core coding region of the hepatitis C viral genome," <i>The Journal of Biological Chemistry</i> , 277:17713-17721, 2002.
	C74	Vernacchio <i>et al.</i> , "Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumococcal-CRM197 conjugate vaccine in healthy toddlers," <i>Vaccine</i> , 20(31-32):3658-67, 2002.
	C75	Villadangos and Ploegh, "Proteolysis in mhc class II antigen presentation: who's in charge," <i>Immunity</i> , 12:233-239, 2000.
	C76	Waldrop <i>et al.</i> , "Normal human cd4+ memory t cells display broad heterogeneity in their activation threshold for cytokine synthesis," <i>J Immunol</i> , 161:5284, 1998.
	C77	Walewski <i>et al.</i> , "Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame," <i>RNA</i> , 7:710-721, 2001.
	C78	Wang <i>et al.</i> , "Sequence variation in the gene encoding the nonstructural 3 protein of hepatitis C virus: evidence for immune selection," <i>J. Mol. Evol.</i> , 54:456-473, 2002.
	C79	Ward <i>et al.</i> , "Cellular immune responses against hepatitis C virus: the evidence base 2002," <i>Clin Exp Immunol</i> , 128(2):195-203, 2002.
	C80	Weekes <i>et al.</i> , "Human CD28-CD28+ T cells contain greatly expanded functional virus-specific memory CTL clones," <i>J. Immunol</i> , 162:7569-7577, 1999.

25766598.1

EXAMINER:	/E.L./	DATE CONSIDERED:	08/07/2008
-----------	--------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Form PTO-1449 (modified)		Atty. Docket No. SONN:077US	Serial No. 10/550,820
List of Patents and Publications for Applicant's			
INFORMATION DISCLOSURE STATEMENT			
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>		Foreign Patent Documents <i>See Page 1-3</i>	Other Art <i>See Page 3-10</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C81	Weekes <i>et al.</i> , "The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo," <i>J. Virol.</i> , 73(3):2099-2108, 1999.
	C82	Weiner <i>et al.</i> , "Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant," <i>Proc Natl Acad Sci U S A.</i> , 92(7):2755-9, 1995.
	C83	Wentworth <i>et al.</i> , "Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome," <i>Int. Immunol.</i> , 8(5):651-659, 1996.
	C84	Wilson <i>et al.</i> , "Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands," <i>J. Immunol.</i> , 163:6424-6434, 1999.
	C85	Wolfel <i>et al.</i> , "Isolation of naturally processed peptides recognized by cytolytic t lymphocytes(ctl) on human emloma cells in association with hla-a2.1," <i>Int. J. Cancer</i> , 57:413-419, 1994.
	C86	Wong <i>et al.</i> , "Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV," <i>Journal of Virology</i> , 75(3):1229-1235, 2001.
	C87	Wong <i>et al.</i> , "Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection," <i>J. Immunol.</i> , 160:1479-1488, 1998.
	C88	Xu <i>et al.</i> , "Synthesis of a novel hepatitis C virus protein by ribosomal frameshift," <i>The EMBO Journal</i> , 20:3840-3848, 2001.
	C89	Zaia <i>et al.</i> , "Cytomegalovirus prevention and treatment in 2000," <i>Hematology</i> , 339-355, 2000.

25766598.1

EXAMINER: /Emily Le/	DATE CONSIDERED:	08/07/2008
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.		

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./